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Abstract Cancer treatment is becoming more and more
individually based as a result of the large inter-individual
differences that exist in treatment outcome and toxicity
when patients are treated using population-based drug
doses. Polymorphisms in genes encoding drug-metaboliz-
ing enzymes and transporters can significantly influence
uptake, metabolism, and elimination of anticancer drugs.
As a result, the altered pharmacokinetics can greatly
influence drug efficacy and toxicity. Pharmacogenetic
screening and/or drug-specific phenotyping of cancer
patients eligible for treatment with chemotherapeutic
drugs, prior to the start of anticancer treatment, can identify
patients with tumors that are likely to be responsive or
resistant to the proposed drugs. Similarly, the identification
of patients with an increased risk of developing toxicity
would allow either dose adaptation or the application of
other targeted therapies. This review focuses on the role of
genetic polymorphisms significantly altering the pharma-
cokinetics of anticancer drugs. Polymorphisms in DPYD,
TPMT, and UGT1A1 have been described that have a major
impact on the pharmacokinetics of 5-fluorouracil, mer-
captopurine, and irinotecan, respectively. For other drugs,
however, the association of polymorphisms with pharma-
cokinetics is less clear. To date, the influence of genetic
variations on the pharmacokinetics of the increasingly used
monoclonal antibodies has hardly been investigated. Some
studies indicate that genes encoding the Fcc-receptor
family are of interest, but more research is needed to
establish if screening before the start of therapy is benefi-
cial. Considering the profound impact of polymorphisms in
drug transporters and drug-metabolizing enzymes on the
pharmacokinetics of chemotherapeutic drugs and hence,
their toxicity and efficacy, pharmacogenetic and pharma-
cokinetic profiling should become the standard of care.
Key Points
Genetic mutations in genes can affect the
pharmacokinetics of drugs.
Altered metabolism of drugs can result in a
decreased therapeutic response and increased
toxicity.
Personalized medicine requires detailed analyses of
the patient’s genome and phenotypic consequences.
1 Introduction
Cancer treatment is becoming more and more individually
based as a result of the large inter-individual differences in
treatment outcome and toxicity. Factors responsible for
inter-individual variability in pharmacokinetics and phar-
macodynamics include drug–drug interactions, ethnicity,
age, renal and liver function, comorbidities, nutritional
status, smoking, and alcohol consumption. However,
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genetic factors may have an even greater impact on drug
efficacy and toxicity [1]. In oncology, genetic variations
can be found either in the tumor genome as somatic
mutations, influencing the choice of chemotherapeutic
treatment or as germline mutations, potentially altering
individual drug pharmacology [2].
Pharmacogenetics is the study of the inherited basis of
inter-individual differences in the efficacy and toxicity of
drugs. Pharmacogenetic screening and/or drug-specific
phenotyping of cancer patients eligible for treatment with
chemotherapeutic drugs, prior to the start of anticancer
treatment, can identify patients with tumors that are likely
to be responsive or resistant to the proposed drugs. Patients
with an unfavorable clinical or genetic make-up would be
candidates for alternative treatment modalities. Similarly,
the identification of patients with an increased risk of
developing toxicity would allow either dose adaptation or
the application of other targeted therapies. Polymorphisms
in the human genome, affecting either expression or
functionality of enzymes and transporters involved in the
distribution and metabolism of anticancer drugs, can
influence drug efficacy and toxicity and thereby the treat-
ment outcome of patients.
The metabolism of xenobiotics is often divided into
three phases: modification (phase I), conjugation (phase II),
and elimination (most often in urine or bile). Phase I drug-
metabolizing enzymes, especially members of the cyto-
chrome P450 (CYP) family, are responsible for oxidation,
reduction, and hydrolysis of drugs [3]. Phase II drug-me-
tabolizing enzymes, such as glutathione S-transferases
(GSTs) and uridine diphosphate glucuronosyltransferases
(UGTs), mainly inactivate or activate drugs by conjugation
reactions [4]. Polymorphisms in these enzymes have fre-
quently been described to influence the pharmacokinetics
of several anticancer drugs. Genes encoding key enzymes
in the anabolic and catabolic pathway of purine and
pyrimidine analogs, such as thiopurine S-methyltransferase
(TPMT) and dihydropyrimidine dehydrogenase (DPD), are
known to contain many polymorphisms and functional
mutations affecting the enzymatic activity [5, 6]. Poly-
morphisms in genes encoding drug efflux transporters, such
as P-glycoprotein (P-gp) and breast cancer resistance pro-
tein (BCRP), can greatly influence gastrointestinal uptake
and excretion of anticancer drugs [7]. Monoclonal anti-
bodies (mAbs) are increasingly being used in the treatment
of cancer. However, limited information is known about
the influence of genetic variations on the pharmacokinetics
of mAbs [8].
This review focuses on the role of genetic polymor-
phisms in altering the pharmacokinetics of anticancer
drugs. Table 1 provides an overview of the currently used
anticancer drugs, their metabolic pathways, and if a genetic
polymorphism significantly alters its pharmacokinet-
ics.Anaplastic lymphoma kinase
2 Cytochrome P450 (CYP)-Mediated Phase
I-Metabolizing Enzymes
Phase I reactions are catalyzed by CYP enzymes, a large
superfamily of membrane-bound proteins, located pre-
dominantly in the endoplasmatic reticulum. The CYP1,
CYP2, and CYP3 families are most frequently involved in
drug metabolism (Table 2). Several factors may cause
inter-individual variations in CYP450 activity: genetic
polymorphisms, changes in physiological conditions such
as age, sex, and disease, or environmental factors such as
smoking, drugs, and certain foods.
The phase I, polymorphic xenobiotic-metabolizing CYP
enzymes can be mainly divided into two classes: Class I,
composed of CYP1A1, CYP1A2, CYP2E1, and CYP3A4,
which are well conserved, do not have many clinically
important functional polymorphisms, and are active in the
metabolism of precarcinogens and drugs. Class II, com-
posed of CYP2B6, CYP2C9, CYP2C19, and CYP2D6,
which are highly polymorphic and active in the metabolism
of drugs, but not of precarcinogens [9]. In this review, we
discuss all three CYP families, with a special focus on
Class II enzymes and their polymorphisms.
2.1 CYP1
In the CYP1 family, only one member, i.e., CYP1A2, has
been associated with altered cancer drug metabolism. The
CYP1A2 enzyme is involved in the metabolism of more
than 20 clinically used drugs and the enzyme accounts for
approximately 15 % of the total CYP450 amount in the
human liver [10]. In lung cancer patients, the CYP1A2*1M
variant has been associated with higher maximum plasma
concentration values after the intake of 150 mg of erlotinib,
suggesting reduced enzyme activity. The impact on drug
efficacy and toxicity is so far unknown [11].
2.2 CYP2
The most important polymorphic enzymes in cancer drug
metabolism are members of the CYP2 family, i.e.,
CYP2A6, CYP2B6, CYP2C9, CYP2C19, and CYP2D6.
The CYP2A6 enzyme is involved in the activation of the
5-fluorouracil (5-FU) prodrug tegafur. In a set of 45 Chi-
nese livers with 20 polymorphic variants, the CYP2A6*4
allele was mainly responsible for decreased in vitro
microsomal formation of 5-FU from tegafur, whereas the
CYP2A6*1B variant was associated with increased in vitro
5-FU formation [12]. In 23 Asian patients treated with
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Table 1 Overview of the currently used anticancer drugs, their metabolic pathways, and if genetic polymorphisms significantly alter their
pharmacokinetics
Anti-cancer drug Target Metabolizing enzymes Transporters/receptors Polymorphism-altering
pharmacokinetics
Alkylating agents
Bendamustine DNA CYP1A2 No, mainly non-
enzymatic
Busulfan DNA CYP2C9, CYP2B6, GSTs Yes [159, 160]
Carmustine DNA Unknown
Chlorambucil DNA GSTs Yes [161]
Cyclophosphamide DNA CYP3A4, CYP3A5, CYP2B6,
CYP2C19, GSTs
Yes [32, 162]
Dacarbazine DNA CYP1A1, CYP1A2, CYP2E1 Unknown
Estramustine DNA Unknown
Hydroxycarbamide DNA Unknown






Melphalan DNA LAT1, LAT2 No [163]
Temozolomide DNA No, mainly non-
enzymatic
Procarbazine DNA CYP2B6, CYP1A4, CYP3A5 Unknown
Thiotepa DNA CYP3A4,CYP3A5 CYP2B6 Yes [9]
Treosulfan DNA No, mainly non-
enzymatic [160]
Antimetabolites
Azacitidine DNA/RNA CDA Yes [164]
Capecitabine DNA/RNA DPD Yes [70]
Cladribine DNA/RNA dCK Unknown
Clofarabine DNA/RNA dCK Yes [92, 93]
Cytarabine DNA/RNA dCK MDR1 Yes [86]
Decitabine DNA/RNA CDA, dCK Yes [90, 95]
Fludarabine DNA/RNA dCK Yes [91]
Fluorouracil DNA/RNA DPD, GSTs Yes [49]
Gemcitabine DNA/RNA CDA, dCK Yes [87–89]
Mercaptopurine DNA/RNA TPMT Yes [72, 73]
Methotrexate DNA/RNA MTHFR SLC, MDR1 Yes [71, 81–84]
Nelarabine DNA/RNA Unknown
Pemetrexed DNA/RNA Unknown
Tegafur DNA/RNA DPD, CYP2A6, CYP2C8, CYP1A2 Yes [57]
Tioguanine DNA/RNA TPMT Yes [165]
Anti-mitotic cytostatics
Cabazitaxel Microtubule CYP3A4 Unknown
Docetaxel Microtubule CYP1B1, CYP2B6, CYP3A4,
CYP3A5
MDR1, BCRP Yes [98, 105]
Paclitaxel Microtubule CYP2C8, CYP3A4, CYP3A5 MDR1, BCRP Yes [98, 105]
Vinblastine Microtubule CYP3A4,CYP3A5, GSTs Unknown
Vincristine Microtubule CYP3A4,CYP3A5, GSTs MDR1 No [166]
Vinorelbine Microtubule CYP2D6, CYP2E1,
CYP3A4,CYP3A5, GSTs
Unknown
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Table 1 continued
Anti-cancer drug Target Metabolizing enzymes Transporters/receptors Polymorphism-altering
pharmacokinetics
Anti-tumor antibacterials
Bleomycin DNA/RNA BLMH, GSTs Yes [167]
Dactinomycin DNA/RNA GSTs MDR1 No [168]
Daunorubicin DNA GSTs MDR1 No [108]
Doxorubicin DNA CYP2B6, CYP3A4, CYP3A5,
CYP2D6, GSTs, UGTs
MDR1, BCRP Yes [106]
Epirubicin DNA UGTs MDR1, SLC No [107]
Idarubicin DNA CYP2D6, CYP2C9, GSTs MDR1 Unknown
Mitomycin DNA GSTs Unknown
Mitoxantrone DNA CYP1B1, CYP3A4, CYP3A5, GSTs MDR1 Unknown
Topoisomerase inhibitors
Etoposide Topoisomerase CYP1A2, CYP2E1, CYP3A4,
CYP3A5, GSTs, UGTs
MDR1 Yes [98]
Irinotecan Topoisomerase CYP3A4, CYP3A5, UGTs MDR1, BCRP Yes [169]
Teniposide Topoisomerase CYP3A4, CYP3A5, UGTs Unknown
Topotecan Topoisomerase CYP3A4, CYP3A5, UGTs BCRP No [170]
Anti-hormones
Abiraterone Androgen receptor Unknown
Anastrozole Aromatase CYP3A4, CYP3A5, CYP2C8,
CYP19A1, UGTs
Yes [171]
Bicalutamide Androgen receptor UGTs MDR1, BCRP Yes [113]
Enzalutamide Androgen receptor CYP2C8, CYP3A4, CYP3A5 Unknown
Exemestane Aromatase CYP3A4, CYP3A5, CYP4A11,
CYP1A2, CYP19A1, UGTs
Yes [172]
Flutamide Aromatase CYP1A2 No [9]
Letrozole Aromatase CYP3A4, CYP3A5, CYP2A6,
CYP19A1
Yes [172]
Megestrol Estrogen receptor Unknown
Nilutamide Androgen receptor Unknown




Fulvestrant Estrogen receptor CYP3A4, CYP3A5 No, mainly non-
enzymatic
Tyrosine kinase inhibitors
Afatinib EGFR No, mainly non-
enzymatic
Axitinib VEGF-R 1-3 CYP3A4, CYP1A2, CYP2C19, UGTs MDR1 No [125]
Bosutinib BCR-ABL/SRc CYP3A4 MDR1 No [115]
Crizotinib ALK CYP3A4, CYP3A5 Unknown
Dabrafenib BRAF CYP2C8, CYP3A4 Unknown
Dasatinib BCR-ABL CYP3A4 MDR1, BCRP No [115]
Erlotinib EGFR
Gefetinib EGFR CYP3A4, CYP3A5, CYP2D6 MDR1, BCRP No [28]
Imatinib BCR-ABL CYP3A4, CYP3A5, CYP2C8 MDR1, BCRP, SLC Yes [118, 119]
Lapatinib HER-2 CYP3A4, CYP3A5, CYP2C19,
CYP2C8
Unknown
Nilotinib BCR-ABL CYP3A4, CYP2C8 BCRP, SLC No [115]
Olaparib PARP CYP3A4 Unknown
Pazopanib Multi CYP3A4, CYP1A2, CYP2C8 Unknown
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irinotecan, oxaliplatin, and tegafur for metastatic gas-
trointestinal cancer, the CYP2A6*4, *7, and *9 variants
were associated with a lower metabolic ratio of tegafur
(area under the curve [AUC] ratio of 5-FU to tegafur) [13].
The impact of CYP2A6 polymorphisms (*4A, *7, and
*9) on tegafur pharmacokinetics was studied in 58 Japa-
nese patients. Although the CYP2A6 genotype did not
affect the AUC of 5-FU, the clearance of tegafur was 58 %
Table 1 continued
Anti-cancer drug Target Metabolizing enzymes Transporters/receptors Polymorphism-altering
pharmacokinetics
Ponatinib BCR-ABL CYP3A4 No [115]
Regorafenib Multi CYP3A4, UGTs Unknown
Ruxolitinib JAK CYP3A4, CYP2C9 Unknown
Sorafenib Multi CYP3A4, UGTs BCRP Yes [126]
Sunitinib Multi CYP3A4, CYP3A5 MDR1, BCRP Yes [174]
Vandetanib Multi CYP3A4 Unknown




Brentuximab CD30 CYP3A4, CYP2D6 Unknown







Rituximab CD20 FCGRT Yes [138–142]
Trastuzumab HER-2 FCGRT Yes [143, 144]
Immunomodulants
Lenalidomide Bone marrow No, mainly non-
enzymatic
Pomalidomide Bone marrow CYP1A2, CYP3A4, CYP2C19,
CYP2D6
Unknown
Thalidomide Bone marrow CYP2C19 Yes [175]
Non-categorized
Asparaginase (PEG) L-Asparagine No [71]
Bortezomib Proteasome CYP3A4, CYP2C19, CYP1A2 No [176]
Carboplatin DNA GSTs Yes [162]
Cisplatin DNA CYP2E1, CYP3A4, CYP3A5, GSTs Yes [177]
Oxaliplatin DNA GSTs Yes [98]
Temsirolimus mTOR CYP3A4 Unknown
Trabectedin DNA CYP3A4, (CYP2C19, CYP2C9,
CYP2D6, CYP2E1)
Unknown
The enzymes and transporters for which genetic polymorphisms are known to significantly alter the pharmacokinetics are indicated in bold
ALK anaplastic lymphoma kinase, BCR-ABL/SRc breakpoint cluster region protein-Abelson murine leukemia viral oncogene homolog/proto-
oncogene tyrosine-protein kinase src, BRAF serine/threonine-protein kinase B-Raf, CD20 cluster of differentiation 20, CD30 cluster of dif-
ferentiation 30, CTLA-4 cytotoxic T-lymphocyte-associated protein 4, CYP cytochrome P450, EGFR epidermal growth factor receptor, GSTs
glutathione, HER-2 human epidermal growth factor receptor 2, JAK janus kinase, mTOR mammalian target of rapamycin, multi various tyrosine
kinases, PARP Poly (ADP-ribose) polymerase, PD-1 Programmed cell death protein, S-transferases, UGT uridine diphosphate glucuronosyl-
transferase, VEGF vascular endothelial growth factor, VEGFR 1-3 vascular endothelial growth factor subtypes 1-3
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Table 2 Polymorphisms in phase I and phase II metabolic enzymes affecting pharmacokinetics of anticancer drugs







Erlotinib CYP1A2 c.1042?43G[A rs2472304 0.13 0.56 0.46 Plasma concentrations [11]
Tegafur CYP2A6 CYP2A6*1A Increased 5-FU formation
[178]
CYP2A6*4A del Decreased 5-FU formation
[178]
CYP2A6*4A-H del CL, AUC [13, 14]
CYP2A6*7
(c.1412T[C)
rs5031016 nr 9 9 10-4 1.1 9 10-2 CL, AUC [13, 14]
CYP2A6*9
(c.-48T[G)
rs28399433 0.08 0.06 0.10 CL, AUC [13, 14, 178]
Cyclofosfamide CYP2B6 CYP2B6*6 CL [15–18, 32]
(c.516G[T) rs3745274 0.37 0.25 0.27
(c.785A[G) rs2279343 nr nr 0.06
Busulfan CYP2C9 CYP2C9*2
(c.430C[T)
rs1799853 0.03 0.13 0.09 Decreased CL [19]
Cyclophosphamide CYP2C19 CYP2C19*2
(c.681G[A)
rs4244285 0.17 0.15 0.19 Reduced CL
[16, 20, 179, 180]
CYP2C19*3
(c.636G[A)
rs4986893 5 9 10-4 2 9 10-4 6 9 10-3
Gefitinib
Tamoxifen












rs5030655 2 9 10-3 9 9 10-3 7.9 9 10-3
CYP2D6*9
(c.841_843del)
rs5030656 5.9 9 10-3 2.7 9 10-2 1.9 9 10-2
CYP2D6*10
(c.100C[T)
rs1065852 0.12 0.22 0.25
CYP2D6*17
(c.320C[T)
rs28371706 0.17 1.8 9 10-2 1.8 9 10-2






rs3957357 nr nr nr Reduced CL busulfan [32, 33]
Thiotepa GSTP1 GSTP1
(c.341C[T)




rs4148323 0.01 0.01 0.02 Reduced CL SN-38
[36–38, 42]
UGT1A1*28a rs8175347
AUC area under the curve, CL clearance, ExAc Exome Aggregation Consortium, ESP Exome Sequencing Project, MAF minor allele frequency,
nr not reported, PK pharmacokinetic, 5-FU 5-fluorouracil
a UGT1A1*28 occurs with a frequency of 0.26–0.31 in Caucasians, 0.42–0.56 in African Americans, and only 0.09–0.16 in Asian populations
[181]
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lower in patients with two variant alleles of CYP2A6 than
in patients with the wild-type or 1 variant allele [14].
The CYP2B6 enzyme converts cyclophosphamide to its
active form 4-hydroxycyclophosphamide. The most com-
mon functionally deficient allele is CYP2B6*6. A total of
644 plasma samples collected over a 5-year period, from
49 B-cell non-Hodgkin lymphoma (NHL) patients aged
B18 years receiving cyclophosphamide (250 mg/m2), were
used to characterize a population pharmacokinetic model.
Polymorphisms in genes including CYP2B6 and CYP2C19
were analyzed. The presence of at least one CYP2B6*6
variant allele was associated with a lower cyclophos-
phamide clearance, as compared with homozygous wild-
type patients, but there was no impact on clinical outcome
[15]. However, several other reports have shown that the
*6 allele is associated with a higher rate of cyclophos-
phamide 4-hydroxylation [16–18]. The overall effect of
CYP2B6*6 expression on the pharmacokinetics and thera-
peutic efficacy/toxicity of cyclophosphamide seems diffi-
cult to predict and would depend on whether the dominant
effect is reduced enzyme expression or increased specific
enzyme activity.
Patients with the CYP2C9 *1/*2 or *2/*2 genotype
undergoing hemopoietic stem cell transplantation may
have decreased metabolism of busulfan as compared with
patients with the wild-type genotype. However, other
genetic and clinical factors may also influence the meta-
bolism of busulfan [19]. The CYP2C19 enzyme plays a
role in the metabolism of cyclophosphamide, ifosfamide,
tamoxifen, and thalidomide. A splice site mutation in exon
5 (CYP2C19*2) and a premature stopcodon in exon 4
(CYP2C19*3) represent the most predominant null alleles
[10]. With regard to cyclophosphamide and CYP2C19
activity, poor metabolizers are theoretically expected to
have a reduced response and low toxicity upon therapy
with cyclophosphamide, as a result of decreased
CYP2C19-mediated activation. However, for CYP2C19*2
and CYP2C19*3, no effect on the pharmacokinetics of
cyclophosphamide was observed in two larger trials con-
ducted in Japanese and European patients [16, 20]. This
might be owing to the fact that cyclophosphamide is acti-
vated via multiple CYP enzyme pathways.
The CYP2D6 gene is the best-studied member of the
CYP family, with over 40 variant alleles [10]. In breast
cancer patients, CYP2D6 plays an important role in the
activation of tamoxifen into endoxifen. In several studies,
clear associations were found between CYP2D6 status and
plasma endoxifen concentrations [21–23]. However, a clear
exposure-response effect remains controversial. In two of
the largest prospective-retrospective studies from BIG 1-98
and ATAC, no association was found between the CYP2D6
genotype and breast cancer recurrence, although genotyp-
ing was performed in tumor DNA and massive departures
from the Hardy–Weinberg equilibrium have been noted
[24–26]. These controversial findings and the partial con-
tribution of the genotype in explaining inter-individual
variability in plasma concentrations of endoxifen imply
that tailored tamoxifen treatment may not be fully realized
through pharmacogenetics of metabolizing enzymes alone
[27].
Lung cancer patients designated as CYP2D6 poor
metabolizers might theoretically have increased concen-
trations of gefitinib as compared with individuals desig-
nated as CYP2D6 extensive metabolizers. However, other
genetic and clinical factors may also influence concentra-
tions of gefitinib. The pharmacokinetics and pharmacoge-
nomics were not associated with significantly different
toxicities, response rates, or survival times with gefitinib
[28, 29].
2.3 CYP3
The CYP3A subfamily is involved in the metabolism of
more than 50 % of clinically used drugs, including several
anticancer drugs such as cyclophosphamide, ifosfamide,
thiotepa, etoposide, teniposide, docetaxel, paclitaxel,
irinotecan, toremifene, vinblastine, vincristine, vinorelbine,
gefitinib, imatinib, and erlotinib. The enzyme activity of
CYP3A ranges widely among subjects, and its activity is
largely affected by non-genetic factors such as age,
endogenous hormone levels, health status, and environ-
mental stimuli. Although approximately 40 allelic variants
have been described for CYP3A4, it has been found that
genetic variability in CYP3A alone is insufficient to
explain its widely ranging enzyme activity and therefore is
not indicated in clinical practice [30]. Recently, it was
demonstrated that the CYP3A4*22 (rs35599367:C[T) and
the CYP3A5*3 (rs776746:A[G) polymorphisms have a
small but clinical insignificant impact on the pharmacoki-
netics of sunitinib, but so far no other studies have
demonstrated an impact on the pharmacokinetics of anti-
cancer drugs [31].
3 Non-CYP Phase II-Metabolizing Enzymes
Several clinical relevant gene polymorphisms associated
with phase II drug metabolism and pharmacokinetics of
anticancer drugs have been reported in the literature. The
GST enzyme family and UGT enzymes have been most
intensively studied (Table 2).
3.1 Glutathione S-Transferase
Four subfamilies of GSTs exist, namely, GSTA, GSTM,
GSTP, and GSTT. GSTA1 plays an important role in the
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detoxification of, busulfan, melphalan, and chlorambucil.
GSTA1*B might be of clinical relevance in busulfan
treatment because two studies in children demonstrated
that the presence of GSTA1*B reduced the clearance of
busulfan up to 30 % [32, 33]. In clinical practice, this
might require dose adjustments of busulfan, at least in
children, based on the GSTA1*B genotype.
In 124 Caucasian patients treated with high-dose
chemotherapy for metastatic breast, ovarian, and testicular
tumors, the clearance of thiotepa and tepa was predomi-
nantly affected by the GSTP1 C341T polymorphism, which
had a frequency of 9.3 %. This allele variant increased
non-inducible thiotepa clearance by 52 % and decreased
tepa clearance by 32 % in heterozygous patients, which
resulted in an increase in combined exposure to thiotepa
and tepa of 45 % in homozygous patients [34].
3.2 Uridine Diphosphate Glucuronosyltransferases
The UGT enzymes are a superfamily of enzymes respon-
sible for the glucuronidation of target substrates. The
transfer of glucuronic acid renders xenobiotics and other
endogenous compounds water soluble, allowing for their
biliary or renal elimination. Unconjugated hyperbiliru-
binemias, such as Gilbert’s syndrome and Crigler–Najjar
syndrome, have been found to be associated with poly-
morphic variants of UGT1A1, especially with UGT1A1*28
[35]. Currently, over 113 different UGT1A1 variants have
been described throughout the gene. These variants can
confer reduced or increased activities, as well as inactive or
normal enzymatic phenotypes.
Irinotecan is converted to its active metabolite SN-38.
SN-38 is further metabolized to SN-38-glucuronide by
various hepatic and extrahepatic UGT1A isozymes, mainly
UGT1A1. Impaired glucuronidation activity of the
UGT1A1 enzyme has been linked with elevated levels of
SN-38, leading to toxicities. UGT1A1*28 involves an extra
TA repeat in the UGT1A1 promoter region and is the
variant most frequently contributing to interpatient vari-
ability in irinotecan pharmacokinetics and toxicities. This
information led to the revision of the irinotecan label by the
US Food and Drug Administration. Both the *28 and *6
alleles have been well studied in regard to pharmaceutical
toxicities. In particular, both alleles have shown associa-
tions with the development of irinotecan toxicities [36–38].
UGT1A1*28 occurs with a frequency of 0.26–0.31 in
Caucasians, and 0.42–0.56 in African Americans, and only
0.09–0.16 in Asian populations [39, 40]. UGT1A1*6 has
allele frequencies in Japanese, Korean, and Chinese pop-
ulations of 0.13, 0.23, and 0.23, respectively [41].
Several studies hypothesized that patients with the *1/*1
genotype would tolerate a higher dose than the standard
recommended dose of 180 mg/m2, while patients with the
*28/*28 genotype would require dose reduction. A
prospective genotype-guided phase I study in colorectal
cancer patients receiving irinotecan monotherapy indeed
demonstrated a maximum tolerated dose (MTD) of 850
mg, 700 mg, and 400 mg in patients with the *1/*1
genotype, *1/*28 genotype, and *28/*28 genotype,
respectively. Interestingly, although the irinotecan AUC
increased according to the different MTDs in each geno-
type group, the mean SN-38 AUC levels were comparable
across the different MTDs in each genotype group [42].
A similar, genotype-guided dose escalation study in
colorectal patients receiving FOLFIRI (5-FU, folinic acid,
irinotecan) identified the MTD of irinotecan to be 370 mg/
m2 and 310 mg/m2 in patients with the *1/*1 genotype and
*1/*28 genotype, respectively. Patients with the *28/*28
genotype were excluded [43]. Recently, it was demon-
strated that high-dose irinotecan (260 mg/m2) FOLFIRI
combined with bevacizumab did not improve the overall
response rate in metastatic colorectal cancer patients with
the *1/*1 or *1/*28 genotype [44]. Whether irinotecan
dose escalation in wild-type UGT1A1 patients contributes
to improved clinical outcome is therefore questionable.
4 Enzymes of Purine and Pyrimidine Metabolism
Structural analogs of nucleobases and nucleosides are used
in the treatment of cancer, viral infections, and inflamma-
tory diseases. These nucleobase and nucleoside analogs are
inactive produgs that are taken up by the cell via specific
nucleobase or nucleoside transporters and subsequently
phosphorylated intracellularly to their pharmacologically
active triphosphate form [45]. The incorporation of
nucleoside triphosphate analogs into DNA causes termi-
nation of DNA elongation and often also resistance to
proofreading exonucleases. Some of these analogs also
inhibit key enzymes (e.g., ribonucleotide reductase,
thymidylate synthase, or dCMP deaminase) involved in the
generation of purine and pyrimidine nucleotides for RNA
and DNA synthesis. Opposing the activation of these pur-
ine and pyrimidine analogs are enzymes that inactivate or
degrade the parent compounds or one of its anabolic
products. Thus, a deficiency of a key enzyme in the ana-
bolic or catabolic pathway of these purine and pyrimidine
analogs will not only affect the clinical efficacy and toxi-
city of the drug but is also likely to alter the pharmacoki-
netics of the drug (Table 3).
5-FU and its oral prodrug capecitabine (Xeloda, F.
Hoffmann-La Roche AG, Basel, Switzerland) are two of
the most frequently prescribed chemotherapeutic drugs for
the adjuvant and palliative treatment of patients with can-
cers of the gastrointestinal tract, breast, and head and neck
[46, 47]. Both 5-FU and capecitabine need to undergo
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Table 3 Genotypes affecting pharmacokinetics of drugs targeting purine and pyrimidine metabolism










DPYD c.1905?1G[A rs3918290 9.0 9 10-4 5.8 9 10-3 5.2 9 10-3 Vmax, t1/2, AUC, CL
[58, 59, 61, 182]
c.1679T[G rs55886062 0 6 9 10-4 3.5 9 10-4 CL [61]
c.2846A[T rs67376798 9.0 9 10-4 5.5 9 10-3 2.6 9 10-3 CL [61]
c.2579delA rs746991079 nr nr 3.3 9 10-5 Vmax (uracil) [62]
c.1129-5923C[G rs75017182 nr nr nr Vmax (uracil) [62]
DPYS c.1506delC rs147965145 2.6 9 10-3 0 2.4 9 10-4 Tmax, Cmax, AUC [66]
UPB1 c.254C[A rs34035085 1.5 9 10-2 0 1.4 9 10-3 Altered uracil flux [68]
Capecitabine MTHFR c.655C[T
(C677T)
rs1801133 0.12 0.35 0.30 t1/2 [70]
Thiopurines TPMT TMPT*2
(c.238G[C)
rs1800462 0 2.3 9 10-3 1.4 9 10-3 TGN [77, 78]
TPMT*3B
(c.460G[A)
rs1800460 1.0 9 10-2 3.7 9 10-2 2.7 9 10-2
TMPT*3C
(c.719A[G)




rs1801133 0.12 0.35 0.30 CL, serum concentrations MTX
[183, 184]
rs1801131 0.16 0.31 0.30 Serum concentrations MTX [184]
ARID5B c.1200-6044T[C rs4948502 nr nr nr Serum concentrations MTX [185]
c.734-5030T[C rs4948496 nr nr nr Serum concentrations MTX [185]
c.276?7693C[A rs4948487 nr nr nr Serum concentrations MTX [185]
ABCC2 c.1234A[G
Knockout model
rs765027508 nr nr 8.2 9 10-6 t1/2 [186]
AUC [187]
SLCO1B1 c.521T[C rs4149056 3.6 9 10-2 0.16 0.13 Serum concentrations MTX,
AUC, CL [185, 188]
c.388A[G rs2306283 0.23 0.40 0.48 Serum concentrations MTX,
AUC, CL [188]
c.1865?248G[A rs4149081 nr nr nr CL [189]







rs60369023 nr nr 2.9 9 10-4 AUC, CL, Cmax [88]
THU induceda AUC, CL [191]
CNTN4 c.2398?70G[T rs4685596 nr nr nr AUC, Cmax [87]
ALOX5AP c.495-204A[G rs4769060 nr nr nr AUC, Vss, Cmax [87]
c.495-523T[C rs3935645 nr nr nr Vss, Cmax [87]
c.341?12C[A rs3803277 0.44 0.44 0.49 Vss, Cmax [87]
DMD c.1331?127G[A rs5928065 nr nr nr AUC, Vss [87]
HEXDC c.15T[G rs1141463 0.38 0.30 0.35 AUC, Vss [87]




AUC area under the curve, ExAc Exome Aggregation Consortium, CDA cytidine deaminase, CL clearance, Cmax maximum plasma concentration,
ESP Exome Sequencing Project, MAF minor allele frequency, nr not reported, PK pharmacokinetic, TGN thioguanine nucleotides, t1/2 elimi-
nation half-life, Vmax maximum enzymatic conversion capacity, Vss volume of distribution at steady state, 5-FU 5-fluorouracil
a CDA deficiency was achieved in mice by treatment with tetrahydrouridine [191]
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enzymatic activation to fluoropyrimidine nucleotides to
exert their cytotoxic effects (Fig. 1a). However, the
degradation of 5-FU plays a significant role as more than
80 % of 5-FU is catabolized by DPD [48]. 5-FU has a
narrow therapeutic index and an increased exposure to
5-FU, owing to a reduced activity of DPD, can thus result
in severe or even lethal toxicity [49]. For DPD activities
within the normal range, conflicting results have been
published as to whether a correlation exists between the
DPD activity and the clearance of 5-FU [50–52]. Com-
pelling results, however, have shown that patients with a
partial or complete DPD deficiency have a reduced
capacity to degrade 5-FU and are at risk of developing
severe 5-FU-associated toxicity [53]. To date, many
mutations and polymorphisms have been described in the
gene encoding DPD (DPYD) and ample evidence has been
provided that carriers of the c.1905?1G[A, c.1679T[C,
c.2846A[T, and c.1129-5923C[G/hapB3 variant have a
strongly increased risk of developing toxicity [6, 54–57].
In a two-compartment model with Michaelis–Menten
elimination, the mean Vmax value was 40 % lower in
patients heterozygous for the c.1905?1G[A mutation in
DPYD compared with controls [58]. Non-compartmental
analysis showed that the mean AUC was 1.5-fold and 1.3-
fold higher in carriers of the c.1905?1G[A mutation
treated with 300 mg/m2 and 450 mg/m2, respectively, when
compared with controls. The mean terminal half-life of
5-FU was 2.1-fold and 1.7-fold longer at 300 mg/m2 and
Fig. 1 Metabolism of drugs interfering with purine and pyrimidine
synthesis. a Metabolism of fluoropyrimidine-containing drugs.
b Thiopurine metabolism. c Methotrexate metabolism. d Nucleoside
metabolism. ABC adenosine triphosphate-binding cassette family of
transporters, CDA cytidine deaminase, DCK deoxycytidine kinase,
DHF dihydrofolate, DHFR dihydrofolate reductase, DPYD dihy-
dropyrimidine dehydrogenase, DPYS dihydropyrimidinase, FBAL
fluoro-b-alanine, FGPS folylpolyglutamate synthase, FUH2 5-flu-
oro-dihydrouracil, FUPA fluoro-b-ureidopropionate, GGH c-glutamyl
hydrolase, HPRT1 hypoxanthine-guanine phosphoribosyltransferase,
MTX methotrexate, MTX-PGs MTX-polyglutamate, NA (deoxy)nu-
cleoside analogs, RFC reduced folate carrier, SLCO1B1 solute carrier
organic anion transporter B, THF tetrahydrofolate, dehydrogenase/
oxidase, TPMT thiopurine-S-methyltransferase, UPB1 b-ureidopropi-
onase, XDH xanthine, 5-FU 5-fluorouracil, 6-MeMP 6-methylmer-
captopurine, 6-MeTIMP 6-methylthioinosine monophosphate, 6-MP
6-mercaptopurine, 6-TGN 6-thioguanine nucleotides, 6-TIMP 6-thioi-
nosine monophosphate, 6-TUA 6-thiouric acid
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450 mg/m2, respectively, compared with controls [58].
Furthermore, a clinical pharmacological study of a patient
with a complete deficiency owing to homozygosity for the
c.1905?1G[A mutation in DPYD demonstrated minimal
catabolism of 5-FU, with a tenfold longer half-life of 5-FU
compared with patients with a normal DPD activity
[59, 60]. A decreased clearance of plasma 5-FU concen-
trations was also noticed for carriers of the c.2846A[T and
c.1679T[G mutations [61]. In addition, an oral uracil
loading test to identify DPD-deficient patients showed
altered pharmacokinetics of uracil in patients who were
carriers for the c.1905?1G[A, c.2846A[T, c.2579delA,
c.1679 T[G, or c.1129-5923C[G mutation [62].
Patients with a complete dihydropyrimidinase (DPYS)
deficiency, the second enzyme of the pyrimidine degrada-
tion pathway, present with strongly elevated levels of
dihydropyrimidines and moderately elevated levels of
uracil and thymine [63]. Patients with a partial DHP defi-
ciency also show an impaired flux through the pyrimidine
degradation pathway and are prone to the development of
severe toxicity after the administration of 5-FU [64–67].
The identification of a healthy individual showing altered
catabolism of uracil due to heterozygosity for a mutation in
UPB1 suggests that also patients with a b-ureidopropionase
deficiency, the third enzyme of the pyrimidine degradation
pathway, might be at risk of developing 5-FU toxicity
[68, 69]. Although methylenetetrahydrofolate reductase
(MTHFR) is not involved in the degradation of capecita-
bine, a borderline decrease in the elimination-half-life of
capecitabine was observed for the c.677C[T mutation in
MTHFR [70]. The c.677C[T mutation in MTHFR reduces
the enzyme activity and presumably increases the level of
5,10-methyleneterahydrofolate, a substrate of thymidylate
synthase. Thus, a direct causal relationship between
MTHFR genotype and apparent elimination half-life of
capecitabine is not likely.
6-Mercaptopurine (6-MP) is an analog of guanine and
hypoxanthine, which is widely used in the treatment of
patients with inflammatory bowel disease and patients with
acute lymphoblastic leukemia [71, 72]. The principal
cytotoxic and immunosuppressive effects of thiopurine
drugs are caused by incorporation of thioguanine nucleo-
tides into DNA or RNA (Fig. 1b). Opposing the principal
enzyme of the anabolic pathway, hypoxanthine-guanine
phosphoribosyl transferase, are the two catabolic enzymes
xanthine oxidase and TPMT. Xanthine oxidase is respon-
sible for oxidation of 6-MP into the inactive metabolite
6-thiouric acid, whereas TPMT methylates 6-MP to form
the inactive metabolite 6-MP. Therefore, TPMT plays a
pivotal role in the production of active thiopurine
metabolites by diverting a proportion of available sub-
strates away from the anabolic pathway of thiopurines to
generate methylated metabolites. To date, more than 35
variants in the gene encoding TPMT have been associated
with decreased TPMT activity [72]. Three variants
TPMT*2, TMPT*3A, and TMPT*3C account for 80–85 %
of intermediate or low enzyme activity in the Caucasian
population [5]. Individuals who are heterozygous carriers
or homozygous for an inherited functional mutation in
TPMT have an increased risk of developing life-threatening
myelosuppressive effects of thiopurines. Patients who are
heterozygous for a TPMT deficiency require a lower dose
of thiopurines (30–50 % of the regular dose) and sub-
stantial reduced doses ([tenfold) or the use of alternative
agents is recommended in patients homozygous for a
TPMT deficiency [72, 73]. Upfront screening of patients
for variants in TPMT, followed by a dose reduction in
heterozygous or homozygous carriers of a variant, reduced
hematological events during thiopurine treatment of
inflammatory bowel disease [74]. Furthermore, a similar
treatment efficacy was obtained in carriers treated with a
reduced thiopurine dose as compared with that observed in
controls [74].
The oral bioavailability of 6-MP is very low owing to
extensive intestinal and hepatic metabolism by xanthine
oxidase [75]. The maximum concentration of 6-MP in
plasma is observed approximately 1.3 h after oral admin-
istration of 6-MP and the elimination half-life is approxi-
mately 1.8 h [76]. One approach to ensure optimal dosing
of thiopurines is to monitor the thiopurine metabolites in
erythrocytes [72]. A population pharmacokinetic model has
been developed to predict the concentrations of thiogua-
nine nucleotides in erythrocytes in pediatric patients with
acute lymphoblastic leukemia and the most influential
covariate examined proved to be the TMPT genotype [77].
In a physiologically based pharmacokinetic model, the
predicted thioguanine nucleotides in erythrocytes in
patients with heterozygous or homozygous variants in the
TPMT gene were twofold and tenfold higher, respectively,
compared with those observed in patients with wild-type
TMPT [78].
Methotrexate (MTX) is most frequently used for the
treatment of patients with rheumatoid arthritis as well as
patients with acute lymphoblastic leukemia. Nevertheless,
MTX can cause severe dose-limiting adverse events and
organ toxicities [79]. MTX is a structural analog of folic
acid and it enters the cell via the reduced folate carrier
(solute carrier family 19 member 1B1, SLC19A1) or the
solute carrier organic anion transporter B1 (SLCO1B1)
(Fig. 1c). In the cytoplasm, MTX is polyglutamated by
folylpolyglutamate synthase, which enhances its retention
in the cell. This process can be reversed by the enzyme c-
glutamyl hydrolase. MTX and MTX-polyglutamate inhibit
dihydrofolate reductase, which catalyses the conversion of
dihydrofolate into tetrahydrofolate. Because reduced
folates are required for both the de novo thymidylate and
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purine synthesis, inhibition of dihydrofolate reductase
results in direct inhibition of both pathways (Fig. 1). In
addition, methotrexate polyglutamate metabolites also bind
directly and inhibit thymidylate synthase and aminoimi-
dazolecarboximide ribonucelotide formyltransferase (pur-
ine de novo pathway) [80]. Efflux of MTX from the cell
occurs via members of the adenosine-50-triphosphate-
binding cassette (ABC) family of transporters, including
ABCB1 [81]. Genetic variations in pharmacokinetic genes
involved in MTX metabolism can be major determinants of
clinical response and toxicity (Table 3) [71, 81–84].
Deoxycytidine kinase (dCK) is responsible for the initial
activation of a number of clinically important anticancer
drugs such as cytarabine, gemcitabine, decitabine, flu-
darabine, and clofarabine (Fig. 1d). Impaired dCK
expression or activity in cells results in resistance to these
drugs, whereas overexpression of dCK in dCK-deficient
cell lines increased the sensitivity of dCK-activated
deoxynucleoside analogs, indicating that dCK plays a key
role in their metabolism and pharmacological activities
[45]. Cytidine deaminase is an important determinant of
the efficacy and cytotoxicity of cytarabine, gemcitabine,
and decitabine because these deoxynucleoside analogs are
readily deaminated and thereby inactivated by cytidine
deaminase [85]. The pharmacokinetics of cytarabine [86],
gemcitabine [87–89], decitabine [90], fludarabine [91], and
clofarabine [92, 93] have been thoroughly investigated in
cancer patients. To date, limited information is only
available regarding the potential impact of altered levels of
the cytidine deaminase gene (CDA) on the pharmacoki-
netics of gemcitabine [87–89, 94] and decitabine [95].
5 Drug Transporters
Polymorphisms in genes encoding drug efflux transporters,
such as P-gp and BCRP, can influence uptake and excretion
of anticancer drugs (Table 4). This contributes to the inter-
Table 4 Polymorphisms in drug transporter genes affecting pharmacokinetics of anticancer drugs





Docetaxel ABCB1 c.1236T[C rs1128203 0.22 0.43 0.54 CL [1]
c.3435T[C rs1045642 0.23 0.48 0.50 CL [192]
Paclitaxel ABCB1 c.1236T[C rs1128203 0.22 0.43 0.54 AUC [193]
c.2677T[A/G rs2032582 nr nr 0.54 AUC [193]
Etoposide ABCB1 c.3435T[C rs1045642 0.77 0.47 0.50 CL [194]
Doxorubicin ABCB1 c.1236T[C rs1128203 0.22 0.43 0.54 Cmax [106]
c.2677T[A/G rs2032582 nr nr 0.54 CL [106]
SLC22A16 c.146A[G rs714368 0.36 0.22 0.25 AUC [195]
c.312T[C rs6907567 0.36 0.22 0.25 AUC [195]
Irinotecan ABCB1 c.1236T[C rs1128203 0.22 0.43 0.54 AUC, CL [110]
Hap*2 CL [111]
Bicalutamide ABCG2 c.421C[A rs2231142 0.03 0.11 0.12 AUC, Tmax, Cmax, t1/2, CL
plasma concentrations
[113]
Topotecan ABCG2 c.421C[A rs2231142 0.03 0.11 0.12 F [196]
Imatinib ABCB1 c.1236T[C rs1128203 0.22 0.43 0.54 Cmin, CL, F [116, 117]
c.2677T[A/G rs2032582 nr nr 0.54 CL, F [117]
c.3435T[C rs1045642 0.23 0.48 0.50 CL, F [117]
Hap*4 Cmin [116]
ABCG2 c.421C[A rs2231142 0.03 0.11 0.12 Cmin, CL [118, 119]
SLC22A1 c.480C[G rs683369 0.05 0.22 0.17 CL, Cmin [128]
Gefitinib ABCG2 c.421C[A rs2231142 0.03 0.11 0.12 Css,min/C1,min [123]
Sunitinib ABCB1 c.2677T[A/G rs2032582 nr nr 0.54 CL [31]
The drug accumulation at the steady-state was assessed as the ratio of Css,min to C1,min, where Css,min was the average pretreatment concentration
on days 8, 15, 22 and 28, and C1,min was the pretreatment concentration before the second dose
AUC area under the curve, ExAc Exome Aggregation Consortium, ESP Exome Sequencing Project, CL clearance, Cmax maximum plasma
concentration, Cmin trough plasma concentration, Css,min/C1,min, F oral bioavailability, MAF minor allele frequency, nr not reported, PK
pharmacokinetic, Tmax time to maximum plasma concentration, t1/2 elimination half-life
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individual variability in pharmacokinetics and, as a con-
sequence, to large differences in treatment response
between cancer patients [7, 96].
P-gp is a member of the ABC superfamily of membrane
transporters and is involved in the active transport of
lipophilic and amphipathic molecules through lipid mem-
branes [97]. P-gp is encoded by the multidrug resistance 1
(MDR1) gene (ABCB1), located at chromosome 7q21. A
number of polymorphisms described in this gene signifi-
cantly influence the pharmacokinetics of several anticancer
drugs. There are three main polymorphisms influencing the
activity of P-gp; the c.2677G[T/A single nucleotide
polymorphism (SNP) in exon 21 leads to a change in the
amino acid sequence from Ala (G) to Ser (T) or Thr (A),
possibly resulting in increased P-gp function [98, 99]. The
second polymorphism is in exon 26 at wobble position
c.3435C[T, resulting in a more than twofold lower P-gp
expression in the duodenum [100]. The third one is also a
synonymous SNP, at c.1236T in exon 12, which does not
directly affect expression of P-gp but may have an indirect
effect such as altering RNA stability for P-gp [101].
BCRP, also called mitoxantrone resistant protein (MXR)
or placenta-specific ABC transporter, is another member of
the ABC transporter superfamily. BCRP is encoded by the
ABCG2 gene located at chromosome 4q22 [102]. A func-
tional SNP (c.421C[A) in exon 5 has been identified,
resulting in a Gln (C) to Lys (A) amino acid substitution,
which proved to be associated with decreased BCRP
expression levels and altered substrate specificity [103].
Docetaxel and paclitaxel are cytotoxic taxanes inhibit-
ing mitosis leading to cancer cell death, which are mainly
used in the treatment of breast, ovarian, and lung cancer
[104]. For taxanes, the ABCB1 gene is considered one of
the best candidates to become a biomarker underlying
variations in clinical responses and toxicity owing to
pharmacokinetic differences [105].
Doxorubicin, an anthracycline widely used as mono- or
combination therapy in the treatment of solid tumors
including breast cancer, is also the substrate of P-gp and
BCRP [106]. Significantly altered clearance and lower
plasma concentration of doxorubicin was observed in
patients harboring any of the three above-described poly-
morphisms in ABCB1. For c.421C[A in ABCG2, no sig-
nificant influence on doxorubicin pharmacokinetics was
observed [106]. Pharmacokinetics of other anthracyclines,
such as epirubicin and daunorubicin, were not altered by
polymorphisms in drug transporter genes [107, 108].
Irinotecan, a topoisomerase I inhibitor, plays a major
role in the treatment of colorectal cancer as monotherapy
or in combination with 5-FU [109]. Elimination pathways
of irinotecan are partially mediated by P-gp and BCRP. A
study investigating polymorphisms in genes encoding these
transporters showed that only the polymorphism
c.1236C[T in ABCB1 was associated with significantly
increased exposure to irinotecan and its active metabolite
SN-38 in individuals homozygous for the T allele [110]. In
addition, a significant association has been observed for
ABCB1 haloptype*2 containing both c.1236C[T,
c.2677G[T/A, and c. 3435C[T, with reduced renal
clearance of irinotecan [111].
Bicalutamide, a non-steroidal pure anti-androgen that
competitively blocks the growth-stimulating effects of
androgens, is used in the treatment of prostate cancer as
monotherapy or in combination with a luteinizing hormone-
releasing hormone analog [112]. P-gp and BCRP are
involved in the disposition of bicalutamide. The pharma-
cokinetic parameters of bicalutamide did not show any
significant differences between ABCB1 genotype groups for
the three main polymorphisms previously described [113].
However, for ABCG2 it was shown that the c.421C[A
polymorphism influenced plasma concentrations of bicalu-
tamide with subjects homozygous for the c.421AA geno-
type exhibiting significantly higher plasma concentrations
than those with the c.421CC or c.421CA genotype [113].
Tyrosine kinase inhibitors (TKIs) are a relatively new
class of oral targeted anticancer therapy. TKIs are designed
to compete with adenosine-50-triphosphate in the tyrosine
kinase receptor mutated and/or over-expressed in cancer
tissues, thereby blocking the signaling important for tumor
growth [114]. Most TKIs are transported by P-gp and
BCRP, thus polymorphisms in genes encoding these
transporters are likely to influence the pharmacokinetics of
TKIs. Most studied in this respect is the first approved TKI;
imatinib, used in the treatment of chronic myeloid leuke-
mia and gastrointestinal stromal tumors [115]. However,
conflicting results have been reported as to whether
ABCB1/ABCG2 polymorphisms affect the pharmacokinet-
ics of imatinib [116–122]. For ABCG2, the results are more
consisted, with the c.421C[A SNP resulting in significant
lower plasma concentrations and changes in the clearance
of imatinib [118, 119]. Another first-generation TKI gefi-
tinib, a selective epidermal growth factor receptor inhibitor
used in the treatment of non-small-cell lung cancer, showed
higher drug accumulation in patients with c.421C[A SNP
in ABCG2 [123]. No relationship with gefitinib AUC was
found with polymorphisms in either ABCB1 or ABCG2
[28]. For the newer second- and third-generation TKIs,
axitinib, bosutinib, nilotinib, dasatinib, sorafenib, and
ponatinib, the substrate affinity for both efflux transporters
is lower than measured for imatinib. Therefore, their effi-
cacy is not significantly affected by polymorphisms in
genes encoding these transporters [115, 124–126].
Increased clearance of sunitinib, a multi-targeted TKI used
in the treatment of renal cell carcinoma, has been shown
for homozygote genotypes of c.2677G[A/T SNP in
ABCB1 [31].
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Another increasingly recognized group of transporters
involved in the pharmacokinetics of anticancer drugs are
the influx transporters of the solute carrier family, also
known as the human organic cation transporter 1 (hOCT1),
encoded by the SLC22A1 gene [127]. hOCT1 is expressed
in several tissues and organs where its activity contributes
to the uptake and elimination of endogenous small organic
toxic by-products and drugs. The c.480C[G polymorphism
in this gene is the most studied one in relation to phar-
macodynamic effects, but only for imatinib has an asso-
ciation been found between genotype and clearance [128].
6 Immunoglobulin-Metabolizing Enzymes
Monoclonal antibodies (mAbs) are increasingly being used
in the treatment of cancer, owing to their high specificity
and activity, combined with the expanding knowledge on
specific tumor targets [129]. mAbs are immunoglobulins
produced with recombinant DNA technology and can be
fully human, humanized chimeric (human/murine), or
murine [130].
The response to mAbs may be difficult to predict owing
to several sources of variability, partly explained by inter-
individual variability in pharmacokinetics [131]. mAbs are
hydrophilic high-molecular-weight proteins and their
pharmacokinetic properties are therefore different from
conventional chemical agents. mAbs used in cancer treat-
ment are, or derive from, human immunoglobulin G (IgG).
Therefore, the pharmacokinetic properties of mAbs are
similar to those of IgG [131]. The IgG structure can be
divided into two identical binding portions (Fab) and a
crystallizable portion (Fc). The Fc portion binds to the
neonatal Fc receptor (FcRn) expressed on phagocytic cells
of the reticuloendothelial system, which is involved in IgG
protection from intracellular catabolism [132]. Intracellular
catabolism is the main route for elimination of IgGs and
mAbs with a Fc portion [133]. Knock-out mice that do not
produce FcRn have a much higher IgG elimination (lower
half-life) than wild-type mice [134].
FcRn is encoded by FCGRT, a gene located on chro-
mosome 19 [135]. To date, little is known about potential
polymorphisms of this gene influencing the pharmacoki-
netics of mAbs [8]. A variable number of tandem repeats
(VNTR) in the FCGRT promotor region has been described
and immunoglobulin therapy proved to be more efficient in
VNTR3/VNTR3 homozygous patients than in VNTR2/
VNTR3 patients [136]. For cetuximab, a significant lower
distribution clearance was shown in VNTR3/VNTR3
patients compared with VNTR2/VNTR3 [8].
In addition, cells of the reticuloendothelial system
express various types of Fcc-receptors, which are also
expected to play a role in the elimination of mAbs, through
internalization and degradation by lysosomes in these cells
after binding of the mAb to the Fcc-receptors [137]. Two
of these Fcc-receptors are FccRIIA and FccRIIIA and
several studies described the influence of a polymorphisms
in FCGR2A or FCGR3A, the genes encoding the FcRIIA
and FcRIIIA receptors, respectively, on therapy outcomes
for rituximab [138–142], trastuzumab [143, 144], and
cetuximab [145–148]. The G to A point mutation described
in the FCGR2A gene generates two FccRIIA allotypes,
with either a histidine (H) or arginine (R) at amino acid
position 131. The T to G substitution described in FCGR3A
generates two FccRIIIA allotypes, with either a pheny-
lalanine (F) or valine (V) at amino acid position 158 in the
membrane-proximal Ig-like loop. Human IgG binds more
strongly to cells homozygous for FccRIIA-131H and
FccRIIIA-158V than to cells homozygous for FccRIIA-
131R and FccRIIIA-158F [149, 150].
Cetuximab, a chimeric immunoglobulin monoclonal
antibody that targets the epidermal growth factor receptor,
is used in the treatment of metastatic colorectal cancer in
combination with chemotherapy or as monotherapy [151].
Several studies explored the role of FCGR polymorphisms
in the treatment outcome of cetuximab, but have conflicting
results. In some studies, FccRIIIA-158F/F was correlated
with response and a longer progression-free survival [146],
while in other studies FccRIIIA-158V/V was associated
with longer progression-free survival [147] or no difference
on progression-free survival at all was observed [145, 148].
For FccRIIA-131 H/H, in two out of three studies, a better
disease control rate and progression-free survival was
observed than those for FccRIIA-131 R/R [147, 148, 152].
Rituximab, a chimeric immunoglobulin monoclonal
antibody that targets the B-cell-surface antigen CD20, is
used in the treatment of diffuse large B-cell lymphoma in
combination with chemotherapy or as monotherapy [153].
For rituximab, several studies showed that FccRIIIA-158V/
V patients had a longer progression-free survival than F
carriers [138–142].
Trastuzumab, a humanized immunoglobulin monoclonal
antibody that targets the human epidermal growth factor
receptor (HER2), is a major therapeutic agent in the
treatment of HER2-positive breast cancer in combination
with chemotherapy or as monotherapy [154]. Some studies
on trastuzumab show a similar effect as observed with
rituximab, with a better clinical response for FccRIIIA-
158V/V patients [143, 144], while others could not confirm
these results [155].
For cetuximab, rituximab, and trastuzumab, the under-
lying mechanism of FCGR polymorphisms was speculated
to be pharmacodynamic, owing to a more efficient
FccRIIa/FccRIIIa-dependent cytotoxicity. However,
because these receptors are also involved in the elimination
of mAbs, it can be hypothesized that these polymorphisms
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also impact mAb clearance. For infliximab, a mAb that is
not used in cancer treatment but instead is frequently used
to control inflammatory diseases, a higher infliximab
elimination rate constant in FccRIIIA-158V/V patients was
observed than in F carriers, leading to a faster infliximab
underexposure and relapse of disease [156]. These findings
can also explain why in vitro studies on rituximab showed
a much stronger correlation, with the concentration leading
to 50 % of maximal lysis about fourfold lower for
FccRIIIA-158V/V patients than for F carriers, than found
in vivo [157].
7 Conclusions
Cancer treatment is becoming more and more individually
based to increase drug efficacy and reduce adverse
responses to therapy. Pharmacogenetic screening and/or
drug-specific phenotyping of cancer patients eligible for
treatment with chemotherapeutic drugs, prior to the start of
anticancer treatment, can not only identify patients with
tumors that are likely to be responsive or resistant to the
proposed drugs but also patients prone to develop severe
toxicity. Ample evidence is now available that polymor-
phisms in DPYD, TPMT, and UGT can profoundly affect
the pharmacokinetics of 5-FU, mercaptopurine, and
irinotecan, respectively [158]. Considering the common
use of these three drugs in the treatment of cancer patients,
the severe toxicity in patients carrying functional poly-
morphisms in these genes, it would be preferable to screen
these patients prior to the start of the therapy. For most
other chemotherapeutic drugs, however, the association of
gene mutations and pharmacokinetics is less clear, which
may be because of a minor impact of genetics compared
with non-genetic factors such as diet, co-medication, health
status, and renal and liver function. These agents may be
candidates for dose individualization by a phenotype-based
approach such as therapeutic drug monitoring.
In the past decades, huge progress has been made in the
rapid characterization of SNPs, enabling the clinical
application of pretreatment pharmacogenetic screening.
However, the scarcity of information on functional char-
acteristics of many SNPs indicates the need for future
research, allowing pharmacogenetic and pharmacokinetic
screenings to become the standard of care.
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